AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
bismuth subsalicylate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4257 | 14882-18-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
bismuth subsalicylate is the active ingredient of Pepto-Bismol and in Kaopectate; used to treat nausea, heartburn, indigestion, upset stomach, diarrhea and other temporary discomforts of the stomach; used with Azoles and other drugs to treat Helicobacter
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 15, 1996 | FDA | PROMETHEUS LABS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Chronic kidney disease | 106.55 | 20.80 | 50 | 4101 | 50141 | 90574155 |
| Diarrhoea | 79.24 | 20.80 | 148 | 4003 | 939042 | 89685254 |
| Cholecystitis chronic | 52.61 | 20.80 | 19 | 4132 | 9807 | 90614489 |
| End stage renal disease | 36.45 | 20.80 | 14 | 4137 | 8557 | 90615739 |
| Nausea | 27.74 | 20.80 | 112 | 4039 | 1110204 | 89514092 |
| Renal injury | 27.39 | 20.80 | 12 | 4139 | 10231 | 90614065 |
| Pancreatic enzymes increased | 24.13 | 20.80 | 6 | 4145 | 864 | 90623432 |
| Cholelithiasis | 22.71 | 20.80 | 19 | 4132 | 52487 | 90571809 |
| Faeces discoloured | 21.65 | 20.80 | 13 | 4138 | 21307 | 90602989 |
| Eye symptom | 21.19 | 20.80 | 4 | 4147 | 157 | 90624139 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Appendicolith | 164.12 | 31.10 | 60 | 4617 | 13396 | 42603262 |
| Blood phosphorus increased | 157.03 | 31.10 | 57 | 4620 | 12468 | 42604190 |
| Appendicitis | 145.92 | 31.10 | 62 | 4615 | 20551 | 42596107 |
| Ventricular fibrillation | 129.35 | 31.10 | 64 | 4613 | 30059 | 42586599 |
| Myasthenia gravis | 115.71 | 31.10 | 49 | 4628 | 16088 | 42600570 |
| Hyperphosphataemia | 111.93 | 31.10 | 45 | 4632 | 12959 | 42603699 |
| Blood uric acid increased | 107.46 | 31.10 | 46 | 4631 | 15501 | 42601157 |
| Abdominal distension | 106.99 | 31.10 | 77 | 4600 | 71658 | 42545000 |
| Dry mouth | 104.44 | 31.10 | 61 | 4616 | 39818 | 42576840 |
| Ascites | 103.69 | 31.10 | 69 | 4608 | 56609 | 42560049 |
| Cardiogenic shock | 99.93 | 31.10 | 57 | 4620 | 35583 | 42581075 |
| Blood cholesterol increased | 92.11 | 31.10 | 49 | 4628 | 26692 | 42589966 |
| Stress | 91.06 | 31.10 | 58 | 4619 | 44154 | 42572504 |
| Analgesic therapy | 90.42 | 31.10 | 32 | 4645 | 6492 | 42610166 |
| Hypophosphataemia | 88.37 | 31.10 | 44 | 4633 | 20901 | 42595757 |
| Neuralgia | 88.35 | 31.10 | 47 | 4630 | 25600 | 42591058 |
| Iron deficiency | 87.38 | 31.10 | 36 | 4641 | 11025 | 42605633 |
| Sleep disorder therapy | 81.26 | 31.10 | 30 | 4647 | 6864 | 42609794 |
| Drug therapy | 76.07 | 31.10 | 28 | 4649 | 6352 | 42610306 |
| Intentional product misuse | 73.46 | 31.10 | 58 | 4619 | 61842 | 42554816 |
| Bacterial infection | 71.24 | 31.10 | 42 | 4635 | 27837 | 42588821 |
| Hyponatraemia | 70.20 | 31.10 | 70 | 4607 | 101392 | 42515266 |
| Chronic kidney disease | 66.46 | 31.10 | 49 | 4628 | 47192 | 42569466 |
| Incorrect route of product administration | 65.75 | 31.10 | 38 | 4639 | 24267 | 42592391 |
| Multiple organ dysfunction syndrome | 65.38 | 31.10 | 66 | 4611 | 96969 | 42519689 |
| End stage renal disease | 64.60 | 31.10 | 33 | 4644 | 16525 | 42600133 |
| Swelling | 59.94 | 31.10 | 49 | 4628 | 54836 | 42561822 |
| Diabetes mellitus | 56.07 | 31.10 | 49 | 4628 | 60038 | 42556620 |
| Chronic obstructive pulmonary disease | 53.99 | 31.10 | 49 | 4628 | 63065 | 42553593 |
| Thrombosis | 50.55 | 31.10 | 49 | 4628 | 68462 | 42548196 |
| Vomiting | 44.59 | 31.10 | 98 | 4579 | 289625 | 42327033 |
| Somnolence | 42.56 | 31.10 | 64 | 4613 | 141041 | 42475617 |
| Sleep disorder | 42.41 | 31.10 | 38 | 4639 | 48057 | 42568601 |
| Abdominal pain | 42.04 | 31.10 | 75 | 4602 | 190396 | 42426262 |
| Drug intolerance | 40.59 | 31.10 | 47 | 4630 | 80377 | 42536281 |
| Bacteroides infection | 37.02 | 31.10 | 13 | 4664 | 2574 | 42614084 |
| Total lung capacity decreased | 36.48 | 31.10 | 14 | 4663 | 3556 | 42613102 |
| Activated partial thromboplastin time prolonged | 35.54 | 31.10 | 22 | 4655 | 15881 | 42600777 |
| Ulcer | 34.87 | 31.10 | 22 | 4655 | 16419 | 42600239 |
| Pulmonary embolism | 34.27 | 31.10 | 53 | 4624 | 119559 | 42497099 |
| Aortic stenosis | 32.85 | 31.10 | 17 | 4660 | 8728 | 42607930 |
| General physical health deterioration | 32.62 | 31.10 | 59 | 4618 | 151187 | 42465471 |
| Capillary permeability increased | 31.47 | 31.10 | 5 | 4672 | 26 | 42616632 |
| Nausea | 31.38 | 31.10 | 105 | 4572 | 396694 | 42219964 |
| Drug hypersensitivity | 31.25 | 31.10 | 46 | 4631 | 99343 | 42517315 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Appendicolith | 190.45 | 19.87 | 61 | 7768 | 14194 | 110567276 |
| Blood phosphorus increased | 170.42 | 19.87 | 58 | 7771 | 16282 | 110565188 |
| Appendicitis | 156.13 | 19.87 | 63 | 7766 | 28401 | 110553069 |
| Ventricular fibrillation | 139.75 | 19.87 | 65 | 7764 | 41248 | 110540222 |
| Myasthenia gravis | 122.76 | 19.87 | 49 | 7780 | 21462 | 110560008 |
| Blood uric acid increased | 122.72 | 19.87 | 49 | 7780 | 21480 | 110559990 |
| Hyperphosphataemia | 120.92 | 19.87 | 45 | 7784 | 16336 | 110565134 |
| Ascites | 109.63 | 19.87 | 73 | 7756 | 92735 | 110488735 |
| Analgesic therapy | 104.82 | 19.87 | 33 | 7796 | 7251 | 110574219 |
| Cardiogenic shock | 103.17 | 19.87 | 59 | 7770 | 57279 | 110524191 |
| Chronic kidney disease | 102.34 | 19.87 | 65 | 7764 | 76226 | 110505244 |
| Sleep disorder therapy | 95.79 | 19.87 | 31 | 7798 | 7440 | 110574030 |
| Abdominal distension | 91.38 | 19.87 | 85 | 7744 | 175018 | 110406452 |
| Drug therapy | 88.40 | 19.87 | 29 | 7800 | 7262 | 110574208 |
| Iron deficiency | 88.06 | 19.87 | 37 | 7792 | 18439 | 110563031 |
| Hypophosphataemia | 87.39 | 19.87 | 44 | 7785 | 33138 | 110548332 |
| Neuralgia | 84.84 | 19.87 | 49 | 7780 | 48429 | 110533041 |
| End stage renal disease | 79.53 | 19.87 | 36 | 7793 | 21437 | 110560033 |
| Stress | 74.84 | 19.87 | 61 | 7768 | 105287 | 110476183 |
| Intentional product misuse | 72.18 | 19.87 | 66 | 7763 | 132838 | 110448632 |
| Multiple organ dysfunction syndrome | 72.18 | 19.87 | 70 | 7759 | 151640 | 110429830 |
| Bacterial infection | 68.72 | 19.87 | 42 | 7787 | 45994 | 110535476 |
| Thrombosis | 57.12 | 19.87 | 53 | 7776 | 108609 | 110472861 |
| Hyponatraemia | 54.62 | 19.87 | 72 | 7757 | 217581 | 110363889 |
| Diabetes mellitus | 53.25 | 19.87 | 49 | 7780 | 99332 | 110482138 |
| Dry mouth | 53.06 | 19.87 | 68 | 7761 | 199880 | 110381590 |
| Abdominal pain | 50.82 | 19.87 | 112 | 7717 | 512877 | 110068593 |
| Chronic obstructive pulmonary disease | 47.50 | 19.87 | 48 | 7781 | 109110 | 110472360 |
| Incorrect route of product administration | 47.39 | 19.87 | 38 | 7791 | 64023 | 110517447 |
| Vomiting | 46.86 | 19.87 | 156 | 7673 | 910519 | 109670951 |
| Nausea | 43.96 | 19.87 | 188 | 7641 | 1235502 | 109345968 |
| Bacteroides infection | 41.06 | 19.87 | 13 | 7816 | 2906 | 110578564 |
| Somnolence | 40.24 | 19.87 | 74 | 7755 | 297375 | 110284095 |
| Activated partial thromboplastin time prolonged | 40.16 | 19.87 | 23 | 7806 | 22345 | 110559125 |
| Pulmonary embolism | 39.15 | 19.87 | 61 | 7768 | 214413 | 110367057 |
| Cholecystitis chronic | 38.60 | 19.87 | 17 | 7812 | 9483 | 110571987 |
| Aortic stenosis | 33.44 | 19.87 | 17 | 7812 | 13042 | 110568428 |
| Antacid therapy | 33.04 | 19.87 | 13 | 7816 | 5471 | 110575999 |
| Blood cholesterol increased | 32.94 | 19.87 | 52 | 7777 | 184733 | 110396737 |
| Anticoagulant therapy | 29.83 | 19.87 | 12 | 7817 | 5349 | 110576121 |
| Total lung capacity decreased | 29.78 | 19.87 | 13 | 7816 | 7101 | 110574369 |
| Capillary permeability increased | 29.45 | 19.87 | 5 | 7824 | 67 | 110581403 |
| Sleep disorder | 28.85 | 19.87 | 51 | 7778 | 198593 | 110382877 |
| Diarrhoea | 28.59 | 19.87 | 157 | 7672 | 1139348 | 109442122 |
| Gout | 27.69 | 19.87 | 22 | 7807 | 36544 | 110544926 |
| Sepsis | 26.37 | 19.87 | 66 | 7763 | 327280 | 110254190 |
| Ulcer | 24.53 | 19.87 | 22 | 7807 | 43094 | 110538376 |
| Hyperlipidaemia | 23.85 | 19.87 | 20 | 7809 | 35828 | 110545642 |
| Blood calcium increased | 23.24 | 19.87 | 15 | 7814 | 18025 | 110563445 |
| Nephrogenic anaemia | 21.25 | 19.87 | 9 | 7820 | 4568 | 110576902 |
| Troponin increased | 20.62 | 19.87 | 17 | 7812 | 29749 | 110551721 |
| Polyserositis | 20.51 | 19.87 | 6 | 7823 | 1028 | 110580442 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA CS | M0002611 | Bismuth |
| MeSH PA | D000930 | Antidiarrheals |
| MeSH PA | D005765 | Gastrointestinal Agents |
| FDA EPC | N0000180183 | Bismuth |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50919 | antiemetic |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diarrhea | indication | 62315008 | |
| Indigestion | indication | 162031009 | |
| Duodenal Ulcer due to H. Pylori | indication | ||
| Traveler's diarrhea | off-label use | 11840006 | |
| Helicobacter pylori-associated gastritis | off-label use | 708164002 | |
| Helicobacter Pylori Gastritis | off-label use | ||
| Alcoholism | contraindication | 7200002 | |
| Lowered convulsive threshold | contraindication | 19260006 | |
| Alcohol intoxication | contraindication | 25702006 | |
| Hepatic failure | contraindication | 59927004 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Disorder of brain | contraindication | 81308009 | DOID:936 |
| Gout | contraindication | 90560007 | DOID:13189 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Seizure disorder | contraindication | 128613002 | |
| Non-infective meningitis | contraindication | 230155003 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pregnancy, function | contraindication | 289908002 | |
| Peripheral nerve disease | contraindication | 302226006 | |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Pseudomembranous enterocolitis | contraindication | 397683000 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cyclooxygenase | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018971 | VUID |
| N0000147252 | NUI |
| D00728 | KEGG_DRUG |
| 4018971 | VANDF |
| C0053792 | UMLSCUI |
| CHEBI:261649 | CHEBI |
| CHEMBL1120 | ChEMBL_ID |
| DB01294 | DRUGBANK_ID |
| C015715 | MESH_SUPPLEMENTAL_RECORD_UI |
| 62TEY51RR1 | UNII |
| 53629521 | PUBCHEM_CID |
| 19478 | RXNORM |
| 4290 | MMSL |
| d01026 | MMSL |
| 001159 | NDDF |
| 409307004 | SNOMEDCT_US |
| 82075003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Percy Medicine | HUMAN OTC DRUG LABEL | 1 | 0322-2222 | LIQUID | 1050 mg | ORAL | OTC Monograph Drug | 8 sections |
| Percy Medicine | HUMAN OTC DRUG LABEL | 1 | 0322-2222 | LIQUID | 1050 mg | ORAL | OTC Monograph Drug | 8 sections |
| Soothe | HUMAN OTC DRUG LABEL | 1 | 0363-0073 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Soothe | HUMAN OTC DRUG LABEL | 1 | 0363-0073 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Soothe | HUMAN OTC DRUG LABEL | 1 | 0363-0736 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Soothe | HUMAN OTC DRUG LABEL | 1 | 0363-0736 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Ultra Strength digestive relief | HUMAN OTC DRUG LABEL | 1 | 0363-1302 | TABLET | 525 mg | ORAL | OTC Monograph Drug | 17 sections |
| Walgreen Stomach Relief | HUMAN OTC DRUG LABEL | 1 | 0363-1423 | TABLET, CHEWABLE | 262 mg | ORAL | OTC Monograph Drug | 16 sections |
| Stomach Relief | HUMAN OTC DRUG LABEL | 1 | 0363-7024 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Stomach Relief | HUMAN OTC DRUG LABEL | 1 | 0363-7024 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| WALGREENULTRA STRENGTH PINK BISMUTH | HUMAN OTC DRUG LABEL | 1 | 0363-7070 | SUSPENSION | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| WALGREENULTRA STRENGTH PINK BISMUTH | HUMAN OTC DRUG LABEL | 1 | 0363-7070 | SUSPENSION | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Walgreen Stomach Relief Ultra Strength | HUMAN OTC DRUG LABEL | 1 | 0363-7071 | SUSPENSION | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Walgreen Stomach Relief Ultra Strength | HUMAN OTC DRUG LABEL | 1 | 0363-7071 | SUSPENSION | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Soothe | HUMAN OTC DRUG LABEL | 1 | 0363-7240 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Soothe | HUMAN OTC DRUG LABEL | 1 | 0363-7240 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| SootheUltra Strength | HUMAN OTC DRUG LABEL | 1 | 0363-7370 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| SootheUltra Strength | HUMAN OTC DRUG LABEL | 1 | 0363-7370 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Walgreen | HUMAN OTC DRUG LABEL | 1 | 0363-9124 | TABLET, CHEWABLE | 262 mg | ORAL | OTC Monograph Drug | 16 sections |
| Walgreen | HUMAN OTC DRUG LABEL | 1 | 0363-9124 | TABLET, CHEWABLE | 262 mg | ORAL | OTC Monograph Drug | 16 sections |
| Walgreen | HUMAN OTC DRUG LABEL | 1 | 0363-9125 | TABLET, FILM COATED | 262 mg | ORAL | OTC Monograph Drug | 16 sections |
| Walgreen | HUMAN OTC DRUG LABEL | 1 | 0363-9125 | TABLET, FILM COATED | 262 mg | ORAL | OTC Monograph Drug | 16 sections |
| Walgreens Bismuth Stomach Relief | HUMAN OTC DRUG LABEL | 1 | 0363-9954 | TABLET, CHEWABLE | 262 mg | ORAL | OTC Monograph Drug | 17 sections |
| Stomach ReliefRegular Strength | HUMAN OTC DRUG LABEL | 1 | 0536-1286 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Stomach ReliefRegular Strength | HUMAN OTC DRUG LABEL | 1 | 0536-1286 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Stomach ReliefUltra | HUMAN OTC DRUG LABEL | 1 | 0536-1287 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Stomach ReliefUltra | HUMAN OTC DRUG LABEL | 1 | 0536-1287 | LIQUID | 525 mg | ORAL | OTC Monograph Drug | 16 sections |
| Major Bismuth Subsalicylate | Human OTC Drug Label | 1 | 0904-7205 | TABLET, CHEWABLE | 262 mg | ORAL | OTC Monograph Drug | 15 sections |
| up and up 5-symptom digestive relief | HUMAN OTC DRUG LABEL | 1 | 11673-122 | TABLET | 262 mg | ORAL | OTC Monograph Drug | 16 sections |
| up and up 5-symptom digestive relief | HUMAN OTC DRUG LABEL | 1 | 11673-122 | TABLET | 262 mg | ORAL | OTC Monograph Drug | 16 sections |